Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock

Amgen (AMGN) shares have recently underperformed, declining 4.2% over the past month against a rising S&P 500 and biomedical industry. While current quarter EPS is projected to decline 8.6% year-over-year with a recent 5% downward revision, full fiscal year earnings are forecast to grow 6.3% and have seen slight upward revisions, supported by positive revenue growth projections. The company has consistently beaten recent earnings and revenue estimates, and Zacks assigns a 'Hold' rating (Zacks Rank #3) with a 'B' Value Style Score, suggesting it trades at a discount to peers despite the near-term stock weakness.

Analysis

Amgen (AMGN) presents a mixed fundamental picture, characterized by recent market underperformance against a backdrop of near-term earnings pressure but a solid long-term execution track record. Over the past month, the stock has declined 4.2%, lagging both the S&P 500's 1.1% gain and its industry's 7% rise. This weakness aligns with projections for the current quarter, where earnings are expected to fall 8.6% year-over-year, and consensus estimates have been revised downward by 5% in the last 30 days. However, this contrasts with the company's history of consistently beating estimates, including a significant 14.45% EPS surprise in the last reported quarter. Looking at the full fiscal year, the outlook is more constructive, with consensus estimates revised up 1.2% over the past month to project 6.3% earnings growth on a 6.6% revenue increase. Nevertheless, growth is forecast to decelerate sharply in the next fiscal year to approximately 1.5% for revenue and 1.8% for earnings. The stock's valuation is noted as favorable, with a Zacks 'B' grade suggesting it trades at a discount to its peers, which, combined with a Zacks #3 'Hold' rank, indicates a neutral near-term outlook.

Key Decisions for Investors

• Given the conflicting signals of near-term earnings headwinds and a discounted valuation, investors may consider holding current positions, as suggested by the Zacks Rank #3 'Hold' rating.
• Value-oriented investors could view the recent 4.2% stock price decline as a potential entry point, capitalizing on the 'B' grade valuation, but must be prepared for the projected 8.6% YoY earnings drop in the current quarter.
• Monitor forward guidance closely, as the projected deceleration in revenue and earnings growth to below 2% for the next fiscal year is a key risk factor that could limit future stock appreciation.